1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

China-US Health Regulatory Dialogue In Crosshairs Amid Biden-Xi Summit

PIC/S Membership Meets Political Pressure

 
• By Brian Yang

Beijing’s application to join an international pharma inspections scheme offers a rare opportunity to revitalize a largely downsized US-China dialogue, but domestic pressure and public opinion may jeopardize the opportunity.

China handshake
China's PIC/S membership application offers rare US-China health collaboration amid Biden-Xi Summit • Source: Shutterstock

Once hailed as among the first countries to open its doors to the US Food and Drug Administration's inaugural overseas offices, China is now having very little if any communications with the US on health policies. This has worried industry observers, who see the lack of dialogue as unhelpful to resolving the plethora of issues facing the two largest economies in the world.

From fentanyl to opioids and other narcotics, from public health science exchange to funding basic research, from US pharma firms' continued commitment to China, to a record number of Chinese companies seeking US approval of their in-house innovations, the need for frequent and normal talks is needed now more than ever

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China Plans Clinical Data Protection By Product Category For First Time

 
• By Xu Hu

After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.

China Approvals Rise But Conditional-To-Full Conversion Slips

 
• By Xu Hu

A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.

Elevar/Hengrui’s Second US CRL A Bad Omen For Multiregional Trials In Asia-Dominant Cancers?

 
• By Dexter Jie Yan

While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.

China Signals Commercial Insurance, Biotech And Foreign-Owned Hospitals As Policy Priorities

 
• By Xu Hu

The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.